| Venetoclax As A Possible Chemopreventive Agent In Adenomatous Polyposis: A Case Report C El Maimouni, M Daca-Alvarez, J Delgado, M Pellisé, F Balaguer Gastroenterologia y hepatologia, 502239, 2024 | | 2024 |
| CD19-Directed CAR T-Cells in a Patient With Refractory MOGAD: Clinical and Immunologic Follow-Up for 1 Year JM Cabrera-Maqueda, M Sepulveda, RR García, G Muñoz-Sánchez, ... Neurology: Neuroimmunology & Neuroinflammation 11 (5), e200292, 2024 | 1 | 2024 |
| 3083–SINGLE CELL MULTIOMIC ANALYSIS OF CLONAL AND TRANSCRIPTIONAL PROGRAMS OF CD19 CAR T CELLS IN THE IMMUNOTHERAPY RESPONSE MG Murillo, A Rill-Hinarejos, JL Trincado, A Bataller, V Ortiz-Maldonado, ... Experimental Hematology 137, 104405, 2024 | | 2024 |
| Chimeric Antigen Receptor T-Cell Postinfusion Fever: Infection Profile, Clinical Parameters, and Biomarkers Trends to Assist Antibiotic Stewardship O Peyrony, N Garcia-Pouton, M Chumbita, C Teijon-Lumbreras, TF Aiello, ... Open Forum Infectious Diseases 11 (7), ofae398, 2024 | | 2024 |
| The development of academic CAR T cells J Delgado, M Juan, G Calvo, Á Urbano-Ispizua The Lancet Haematology 11 (7), e484-e485, 2024 | | 2024 |
| Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC) P Abrisqueta, E González-Barca, C Ferrà, E Ríos-Herranz, MF de la Mata, ... Eclinicalmedicine 73, 102642, 2024 | | 2024 |
| InsT‐ALLing CD7 chimeric antigen receptors before transplantation J Delgado British Journal of Haematology 204 (6), 2155-2156, 2024 | | 2024 |
| Biomarkers of efficacy and safety of the academic BCMA-CART ARI0002h for the treatment of refractory multiple myeloma A Oliver-Caldes, M Español-Rego, A Zabaleta, V González-Calle, ... Clinical Cancer Research 30 (10), 2085-2096, 2024 | 2 | 2024 |
| The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B‐cell malignancies H Brillembourg, N Martínez‐Cibrián, M Bachiller, L Alserawan, ... British Journal of Haematology 204 (5), 1649-1659, 2024 | 2 | 2024 |
| La thérapie CAR: la place des institutions académiques dans leur production J Delgado Bulletin de l'Académie Nationale de Médecine, 2024 | 3 | 2024 |
| Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation H Playa-Albinyana, F Arenas, R Royo, A Giró, I López-Oreja, M Aymerich, ... Leukemia 38 (3), 557-569, 2024 | 4 | 2024 |
| Infection epidemiology in relation to different therapy phases in patients with haematological malignancies receiving CAR T‐cell therapy N Garcia‐Pouton, V Ortiz‐Maldonado, O Peyrony, M Chumbita, TF Aiello, ... European Journal of Haematology 112 (3), 371-378, 2024 | 1 | 2024 |
| The academic point‐of‐care anti‐CD19 chimeric antigen receptor T‐cell product varnimcabtagene autoleucel (ARI‐0001 cells) shows efficacy and safety in the treatment of relapsed … N Martínez‐Cibrián, V Ortiz‐Maldonado, M Español‐Rego, A Blázquez, ... British Journal of Haematology 204 (2), 525-533, 2024 | 4 | 2024 |
| Integrative single-cell multi-omics of CD19CARpos and CARneg T cells suggest drivers of immunotherapy response in B-cell neoplasias M Guerrero-Murillo, A Rill-Hinarejos, JL Trincado, A Bataller, ... bioRxiv, 2024.01. 23.576878, 2024 | | 2024 |
| A low total metabolic tumor volume independently predicts for a longer time to first treatment in initially observed, low tumor burden follicular lymphoma P Mozas, S Casanueva‐Eliceiry, A Rivero, Á Serna, M Simó, S Rodríguez, ... Hematological Oncology 42 (1), e3235, 2024 | 1 | 2024 |
| Lymphodepletion–an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle B Lickefett, L Chu, V Ortiz-Maldonado, L Warmuth, P Barba, M Doglio, ... Frontiers in Immunology 14, 1303935, 2023 | 16 | 2023 |
| IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia C Syrykh, B Pons-Brun, N Russiñol, H Playa-Albinyana, T Baumann, ... Blood Advances 7 (23), 7384-7391, 2023 | 2 | 2023 |
| The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL A Visentin, T Chatzikonstantinou, L Scarfò, A Kapetanakis, ... American Journal of Hematology 98 (12), 1856-1868, 2023 | 10 | 2023 |
| Varnimcabtagene Autoleucel (ARI-0001) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Richter Transformation (RT) V Ortiz-Maldonado, N Martinez-Cibrian, GDC Balguerías, ... Blood 142, 3483, 2023 | 1 | 2023 |
| ARI0002h (Cesnicabtagene Autoleucel), an Academic Point-of-Care B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Strategy: Activity and Safety … A Oliver-Caldes, V Gonzalez-Calle, V Cabañas, N Lopez-Muñoz, ... Blood 142, 1026, 2023 | 3 | 2023 |
Neus VillamorHospital Clinic在 clinic.cat 的电子邮件经过验证
